If pharma wants to help the NHS improve outcomes, it needs to do so through a true partnership rather than a transactional relationship. That’s according to Daiichi Sankyo’s UK managing ...

“This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased,” said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. “With the results ...

"This year’s ASCO marks the fourth in a row where potential practice-changing ENHERTU data will be showcased," said Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo. "With the results of ...

Daiichi Sankyo and MSD have announced the first subject dosing in the Phase III Ideate-Esophageal01 trial, assessing the safety and efficacy of ifinatamab deruxtecan (I-DXd) in individuals with ...

Daiichi Sankyo has signed a deal worth up to $300 million with South Korean biotech Alteogen to develop a subcutaneous version of its AstraZeneca-partnered cancer drug Enhertu. Alteogen will ...

(Image/Reuters) Northern TK Venture (NTK), a Singapore-based indirect arm of Malaysia’s IHH Healthcare, has raised its damages claims against Japanese pharma firm Daiichi Sankyo Company by ...

IHH Healthcare, supported by Mitsui, has increased its compensation claim against Daiichi Sankyo to $1.3 billion in the Tokyo District Court, related to the Fortis Healthcare acquisition.

May 29, 2025 Merck, Daiichi pull US ... sought from Japan's Daiichi Sankyo over its Fortis Healthcare stake buy to up to 109.3 billion rupees ($1.28 billion). Pharma stocks recover from initial ...

IHH Healthcare said on Tuesday its unit has filed a petition in a Tokyo court to revise damages sought from Japan's Daiichi Sankyo over its Fortis Healthcare stake buy to up to 109.3 billion rupees ...

The ideas and opinions expressed in this Data Supplement do not necessarily reflect those of the American Society of Clinical Oncology (ASCO ... Pharmaceutical, Daiichi Sankyo, Lilly Japan, Yakult ...